NeoGenomics, Inc.
16.59USD
+0.2000 (+1.22%)
Fetching financial statements from SEC filings…
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on NEO.
| In $M except per-share | Q2 FY26 | Q1 FY26 | Q4 FY25* | Q3 FY25 | Q2 FY25 | Q1 FY25 | Q4 FY24* | Q3 FY24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 202 | 187 | 190 | 188 | 181 | 168 | 172 | 168 |
| Cost of Revenue | 110 | 106 | 107 | 107 | 104 | 95 | 95 | 93 |
| Gross Profit | 92 | 81 | 83 | 80 | 77 | 73 | 77 | 75 |
| Operating Income | -10 | -18 | -13 | -27 | -48 | -28 | -18 | -21 |
| Net Income | 2 | -17 | -10 | -27 | -45 | -26 | -15 | -18 |
| EPS (Diluted) | — | — | — | — | — | — | — | — |
* Derived period (computed from FY minus reported quarters). Source: SEC filings (EDGAR)